OBJECTIVE: To determine if patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiation have improved outcomes. STUDY DESIGN: A retrospective search was used to identify patients with OPSCC treated with concurrent chemoradiation. Pretreatment biopsy specimens were tested for HPV-16 infection and p16 expression. METHODS: Forty-four patients with OPSCC treated with concurrent chemotherapy and intensity-modulated radiation therapy were identified. Eligibility criteria included a minimum two years of follow-up, or biopsy-proven recurrence. In situ hybridization was applied to archival tumor specimens, with HPV-16-positive status defined as positive staining of tumor cell nuclei. p16 expression was assessed by immunohistochemistry. RESULTS: Twenty-seven tumors (61%) were positive for HPV-16 and 29 tumors (66%) expressed p16. HPV-16 infection was highly correlated with p16 expression (P < 10(-7)). Three-year disease-free and overall survival for all patients was 66 percent and 79 percent respectively. Patients with tumors infected with HPV-16 had improved overall (OS) and disease-free survival (DFS) after chemoradiation (OS: hazard ratio [HR] = 0.21, P = 0.01; DFS: HR = 0.30, P = 0.02). CONCLUSION: Patients with OPSCC tumors that are infected with HPV-16 have improved survival after treatment with concurrent chemoradiation.
OBJECTIVE: To determine if patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiation have improved outcomes. STUDY DESIGN: A retrospective search was used to identify patients with OPSCC treated with concurrent chemoradiation. Pretreatment biopsy specimens were tested for HPV-16 infection and p16 expression. METHODS: Forty-four patients with OPSCC treated with concurrent chemotherapy and intensity-modulated radiation therapy were identified. Eligibility criteria included a minimum two years of follow-up, or biopsy-proven recurrence. In situ hybridization was applied to archival tumor specimens, with HPV-16-positive status defined as positive staining of tumor cell nuclei. p16 expression was assessed by immunohistochemistry. RESULTS: Twenty-seven tumors (61%) were positive for HPV-16 and 29 tumors (66%) expressed p16. HPV-16 infection was highly correlated with p16 expression (P < 10(-7)). Three-year disease-free and overall survival for all patients was 66 percent and 79 percent respectively. Patients with tumors infected with HPV-16 had improved overall (OS) and disease-free survival (DFS) after chemoradiation (OS: hazard ratio [HR] = 0.21, P = 0.01; DFS: HR = 0.30, P = 0.02). CONCLUSION:Patients with OPSCC tumors that are infected with HPV-16 have improved survival after treatment with concurrent chemoradiation.
Authors: James S Lewis; Wade L Thorstad; Rebecca D Chernock; Bruce H Haughey; James H Yip; Qin Zhang; Samir K El-Mofty Journal: Am J Surg Pathol Date: 2010-08 Impact factor: 6.394
Authors: Yin Wu; Marshall R Posner; Lisa M Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Changwan Lu; Sana Iqbal; Jochen Lorch; Nicholas J Sarlis; Robert I Haddad; Kevin J Cullen Journal: Cancer Date: 2011-08-25 Impact factor: 6.860
Authors: Maria B Koenigs; Armida Lefranc-Torres; Juliana Bonilla-Velez; Krupal B Patel; D Neil Hayes; Krzysztof Glomski; Paul M Busse; Annie W Chan; John R Clark; Daniel G Deschler; Kevin S Emerick; Rebecca J Hammon; Lori J Wirth; Derrick T Lin; Edmund A Mroz; William C Faquin; James W Rocco Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Claudia Lill; Gabriela Kornek; Barbara Bachtiary; Edgar Selzer; Christian Schopper; Martina Mittlboeck; Martin Burian; Friedrich Wrba; Dietmar Thurnher Journal: Wien Klin Wochenschr Date: 2011-03-30 Impact factor: 1.704
Authors: L Mannarini; V Kratochvil; L Calabrese; L Gomes Silva; P Morbini; J Betka; M Benazzo Journal: Acta Otorhinolaryngol Ital Date: 2009-06 Impact factor: 2.124
Authors: Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha Journal: Head Neck Date: 2012-08-21 Impact factor: 3.147